GlycoMimetics Announces Transition Plan for Board of Directors
- Current Board Member Tim Pearson to become Board Chair effective at the close of the company’s annual meeting on
May 17, 2019 - Longtime Board Chair
M. James Barrett , Ph.D., and Board Member John Magnani, Ph.D., will not seek re-election
“I am deeply grateful for Jim’s long-time service on the board and his strong support of the company since its founding. Over the years, he has helped
Mr. Pearson is the former Chief Financial Officer and Executive Vice President for
“I am honored to be nominated as the next GlycoMimetics’ Board Chair and look forward to working with the board and management in this expanded role,” said Mr. Pearson. “I thank Jim for his vision and leadership which has brought
About
GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.
Forward-Looking Statements
This press release contains forward-looking statements regarding the clinical development and regulatory pathway and potential benefits and impact of the company’s drug candidates. Actual results may differ materially from those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005957/en/
Source:
Investor Contact:
Shari Annes
Phone: 650-888-0902
Email: sannes@annesassociates.com
Media Contact:
Jamie Lacey-Moreira
Phone: 410-299-3310
Email: jamielacey@presscommpr.com